JP2002523475A5 - - Google Patents

Download PDF

Info

Publication number
JP2002523475A5
JP2002523475A5 JP2000567247A JP2000567247A JP2002523475A5 JP 2002523475 A5 JP2002523475 A5 JP 2002523475A5 JP 2000567247 A JP2000567247 A JP 2000567247A JP 2000567247 A JP2000567247 A JP 2000567247A JP 2002523475 A5 JP2002523475 A5 JP 2002523475A5
Authority
JP
Japan
Prior art keywords
examples
purogene
bio
name
mixing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000567247A
Other languages
English (en)
Other versions
JP2002523475A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/020060 external-priority patent/WO2000012137A1/en
Publication of JP2002523475A publication Critical patent/JP2002523475A/ja
Publication of JP2002523475A5 publication Critical patent/JP2002523475A5/ja
Pending legal-status Critical Current

Links

Description

実施例３〜９（比較例）
下記成分を混合することにより、水性組成物７種を調製した：
Figure 2002523475
Figure 2002523475
 （１）各組成物は、１００％ｗ／ｖとするのに充分な量のＵＳＰ水を含有する。
（２）Bio-Cide International Inc.からPUROGENE（商標）の名称で市販されている生成物

JP2000567247A 1998-09-02 1999-09-01 防腐したシクロデキストリン含有組成物 Pending JP2002523475A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9885498P 1998-09-02 1998-09-02
US60/098,854 1998-09-02
PCT/US1999/020060 WO2000012137A1 (en) 1998-09-02 1999-09-01 Preserved cyclodextrin-containing compositions

Publications (2)

Publication Number Publication Date
JP2002523475A JP2002523475A (ja) 2002-07-30
JP2002523475A5 true JP2002523475A5 (ja) 2006-10-19

Family

ID=22271266

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000567247A Pending JP2002523475A (ja) 1998-09-02 1999-09-01 防腐したシクロデキストリン含有組成物

Country Status (6)

Country Link
US (3) US6358935B1 (ja)
EP (1) EP1109581A1 (ja)
JP (1) JP2002523475A (ja)
AU (1) AU757896B2 (ja)
CA (1) CA2342797A1 (ja)
WO (1) WO2000012137A1 (ja)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012137A1 (en) * 1998-09-02 2000-03-09 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
US20040214829A1 (en) * 2000-07-14 2004-10-28 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
AU2005220199B2 (en) * 2000-07-14 2007-03-08 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US8858961B2 (en) 2000-07-14 2014-10-14 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20050026924A1 (en) * 2000-07-14 2005-02-03 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
CA2402405C (en) 2000-07-14 2008-02-12 Allergan Sales, Inc. Compositions containing alpha-2-adrenergic agonist components
BR0112461A (pt) 2000-07-14 2003-07-22 Allergan Inc Composições que contém componentes terapeuticamente ativos tendo uma solubilidade aumentada
US7112533B2 (en) * 2000-08-31 2006-09-26 Micron Technology, Inc. Plasma etching system and method
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US20020198209A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US20040214797A1 (en) * 2001-05-07 2004-10-28 Allergan, Inc. Preserved pharmaceutical compositions comprising cyclodextrins
US6566347B1 (en) * 2001-08-22 2003-05-20 Duquesne University Of The Holy Ghost Controlled release pharmaceutical
WO2004028477A2 (en) * 2002-09-29 2004-04-08 Surmodics, Inc. Methods for treatment and/or prevention of retinal disease
US20040191332A1 (en) * 2003-03-27 2004-09-30 Allergan, Inc. Preserved ophthalmic compositions
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20070224278A1 (en) * 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20070020196A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
AU2011235943B2 (en) * 2003-12-31 2014-06-26 Cydex Pharmaceuticals, Inc Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
HUE032527T2 (en) * 2003-12-31 2017-09-28 Cydex Pharmaceuticals Inc Sulphoalkyl ether cyclodextrin and corticosteroid inhalation preparation
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
AU2005209201B2 (en) 2004-01-20 2010-06-03 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
LT1713504T (lt) 2004-01-30 2017-09-11 Zoetis Services Llc Antimikrobinis konservantas, skirtas multi-dozinėms kompozicijoms, panaudojant beta-ciklodekstrinus, skirtas skystoms vaisto formoms
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
US20050234018A1 (en) * 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
CA2505836C (en) * 2004-05-06 2013-08-27 Alcon Inc. Topical brimonidine tartrate formulations that lack chlorine dioxide
US6969706B1 (en) * 2004-05-12 2005-11-29 Allergan, Inc. Preserved pharmaceutical compositions comprising cyclodextrins
WO2006014484A2 (en) * 2004-07-02 2006-02-09 Surmodics, Inc. Methods and devices for the treatment of ocular conditions
US20060006361A1 (en) * 2004-07-08 2006-01-12 Joseph Callerame Clathrate of chlorine dioxide
CA2573668A1 (en) * 2004-07-12 2006-02-16 Allergan, Inc. Ophthalmic compositions and methods for treating ophthalmic conditions
WO2006043965A1 (en) * 2004-10-14 2006-04-27 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
JP4758654B2 (ja) * 2005-01-26 2011-08-31 株式会社ソフト９９コーポレーション 消臭方法
WO2006110487A1 (en) * 2005-04-08 2006-10-19 Surmodics, Inc. Sustained release implants for subretinal delivery
CA2615108A1 (en) * 2005-07-13 2007-01-18 Santen Pharmaceutical Co., Ltd. Preservative composition for ophthalmic use
US7799331B2 (en) 2005-08-04 2010-09-21 Taro Pharmaceutical North America, Inc. Oral suspension of prednisolone acetate
US8920827B2 (en) * 2005-10-21 2014-12-30 Wake Forest University Health Sciences Keratin bioceramic compositions
US20070249572A1 (en) * 2005-12-20 2007-10-25 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070197487A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an increased lung deposition
US20070160542A1 (en) * 2005-12-20 2007-07-12 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070197486A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
US20070185066A1 (en) * 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070178050A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an increased lung depositon
US20070178049A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070238789A1 (en) * 2006-03-31 2007-10-11 Chin-Ming Chang Prednisolone acetate compositions
US8668676B2 (en) * 2006-06-19 2014-03-11 Allergan, Inc. Apparatus and methods for implanting particulate ocular implants
US20080097335A1 (en) 2006-08-04 2008-04-24 Allergan, Inc. Ocular implant delivery assemblies
US7662820B2 (en) 2006-10-30 2010-02-16 Sanrx Pharmaceuticals, Inc. Dipterinyl calcium pentahydrate (DCP) and therapeutic methods based thereon
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
US7935271B2 (en) * 2007-08-23 2011-05-03 Ken Harrison Compositions, systems, and/or methods involving chlorine dioxide
US8563046B2 (en) 2007-08-23 2013-10-22 Dharma IP, LLC Compositions, systems, and/or methods involving chlorine dioxide (“ClO2”)
US7999741B2 (en) * 2007-12-04 2011-08-16 Avaya Inc. Systems and methods for facilitating a first response mission at an incident scene using precision location
EP2294003A1 (en) 2008-05-30 2011-03-16 Ken Harrison Systems, methods, and compositions involving chlorine dioxide and zeolite
TW201010727A (en) * 2008-09-03 2010-03-16 Alcon Res Ltd Pharmaceutical composition having relatively low ionic strength
US8545554B2 (en) * 2009-01-16 2013-10-01 Allergan, Inc. Intraocular injector
CN102883708A (zh) * 2010-04-07 2013-01-16 阿勒根公司 用于眼用组合物的防腐剂联合
WO2011127139A2 (en) * 2010-04-07 2011-10-13 Allergan, Inc. Combinations of preservative compositions for ophthalmic formulations
CA2812997A1 (en) * 2010-09-16 2012-03-22 Dharma IP, LLC Methods, compositions, and devices for managing chlorine dioxide release
BR112014012985B1 (pt) 2011-11-29 2020-05-12 Jurox Pty Ltd Composição farmacêutica injetável, seu método de produção e uso, bem como método de conservação de uma composição farmacêutica injetável e uso de pelo menos um co-solvente e pelo menos um conservante
HUE060093T2 (hu) 2012-03-15 2023-01-28 Boehringer Ingelheim Vetmedica Gmbh Gyógyszerészeti tablettakészítmény az állatgyógyászati ágazat számára, eljárás annak elõállítására és annak alkalmazása
WO2014074605A1 (en) * 2012-11-08 2014-05-15 Allergan, Inc. Preserved topical formulations with improved antimicrobial activity
PL3021832T3 (pl) 2013-07-19 2021-08-23 Boehringer Ingelheim Vetmedica Gmbh Konserwowana ciekła wodna kompozycja farmaceutyczna zawierająca eteryfikowane pochodne cyklodekstryny
DK2925305T3 (en) 2013-12-04 2016-10-10 Boehringer Ingelheim Vetmedica Gmbh Improved pharmaceutical compositions of pimobendan.
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
CN117355311A (zh) 2022-05-05 2024-01-05 阿卜杜拉·库尔卡耶夫 用于恢复生物体生理过程和细胞的药物组合物

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53113017A (en) * 1977-03-15 1978-10-03 Asahi Denka Kogyo Kk Food preservatives
US4383992A (en) 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
US4470965A (en) 1982-10-27 1984-09-11 Usv Pharmaceutical Corporation Celiprolol for the treatment of glaucoma
JPS59152320A (ja) * 1983-02-17 1984-08-31 Takeda Chem Ind Ltd 水性製剤
JPS60149530A (ja) * 1984-01-13 1985-08-07 Takeda Chem Ind Ltd 水性製剤
JPS60204712A (ja) * 1984-03-29 1985-10-16 Ss Pharmaceut Co Ltd 塩酸メクリジンの安定化液状組成物
US4728509A (en) 1985-08-19 1988-03-01 Takeda Chemical Industries, Ltd. Aqueous liquid preparation
JPS62292719A (ja) * 1986-06-12 1987-12-19 Kaken Pharmaceut Co Ltd 外用澄明水溶性製剤
JPS63141543A (ja) * 1986-12-04 1988-06-14 Kamimurakatsujirou Shoten:Kk 甘酢生姜の製造方法
JP2577049B2 (ja) 1987-06-04 1997-01-29 三共株式会社 シクロスポリン製剤
US4877774A (en) * 1987-09-09 1989-10-31 The United States Of America As Represented By The Department Of Health And Human Services Administration of steroid hormones
US5068226A (en) * 1987-12-07 1991-11-26 Cyclex, Inc. Pharmaceutical preparations containing cyclodextrins and their use in iontophoretic therapies
US4975428A (en) 1988-05-31 1990-12-04 Iolab Corporation Treatment of glaucoma using phosphodiesterase inhibitors
US5229370A (en) * 1988-08-15 1993-07-20 Ammeraal Robert N Water soluble branched beta cyclodextrin steroid complex
CA2003198C (en) * 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
JPH02262518A (ja) 1989-04-03 1990-10-25 Kaken Pharmaceut Co Ltd 眼圧調整剤
JPH0348655A (ja) 1989-07-14 1991-03-01 Shionogi & Co Ltd プロスタグランジンｄ↓２類の安定化
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9001987D0 (en) 1990-01-29 1990-03-28 Janssen Pharmaceutica Nv Improved cyclodextrin based erythropietin formulation
US5227372A (en) 1990-03-07 1993-07-13 Children's Medical Center Corporation Method for retaining ophthalmological agents in ocular tissues
US5124154A (en) 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
TW200402B (ja) * 1990-08-13 1993-02-21 Senju Pharma Co
LU87843A1 (fr) * 1990-11-15 1992-08-25 Cird Galderma Gel aqueux a base d'acide retinoique et d'hydroxypropyl-beta-cyclodextrine et son utilisation en medecine humaine et en cosmetique
JP3048655B2 (ja) 1991-02-22 2000-06-05 三菱化学株式会社 α‐オレフィン重合体の製造
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
CA2136321A1 (en) * 1992-05-22 1993-12-09 Takahiro Ogawa Pharmaceutical composition for use in glaucoma treatment
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5362758A (en) 1992-09-18 1994-11-08 Pfizer Inc. Ophthalmic piroxicam solution
TW401300B (en) 1992-12-25 2000-08-11 Senju Pharma Co Antiallergic composition for ophthalmic or nasal use
US5494901A (en) 1993-01-05 1996-02-27 Javitt; Jonathan C. Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
FR2714067B1 (fr) * 1993-12-22 1996-01-12 Commissariat Energie Atomique Nouveaux dérivés de cyclodextrines, utilisables en particulier pour solubiliser des composés chimiques hydrophobes tels que des médicaments, et leur procédé de préparation.
US5714137A (en) * 1994-08-12 1998-02-03 The Procter & Gamble Company Uncomplexed cyclodextrin solutions for odor control on inanimate surfaces
US5576311A (en) * 1994-11-30 1996-11-19 Pharmos Corporation Cyclodextrins as suspending agents for pharmaceutical suspensions
PT877600E (pt) * 1996-08-09 2004-02-27 Alcon Mfg Ltd Sistemas conservantes para composicoes farmaceuticas contendo ciclodextrinas
SE520645C2 (sv) * 1996-11-15 2003-08-05 Interhealth Ab Terapeutiska och kosmetiska kompositioner, deras användning och metod för framställning därav
US6106738A (en) * 1997-06-09 2000-08-22 The Procter & Gamble Company Uncomplexed cyclodextrin compositions for odor control
MA24577A1 (fr) * 1997-06-26 1998-12-31 Procter & Gamble Procedes et compositions de reduction de micro-organisme pour produits alimentaires
EP0938896A1 (en) * 1998-01-15 1999-09-01 Novartis AG Autoclavable pharmaceutical compositions containing a chelating agent
SE9801647D0 (sv) * 1998-05-12 1998-05-12 Interhealth Ab Therapeutic composition
WO2000012137A1 (en) * 1998-09-02 2000-03-09 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
US20020198174A1 (en) * 2001-05-07 2002-12-26 Allergan Sales, Inc. Disinfecting and solubilizing steroid compositions
AU2879100A (en) * 1999-02-12 2000-08-29 Miles A. Libbey Iii Formulation and system for intra-oral delivery of pharmaceutical agents
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
US6696426B2 (en) * 2000-08-22 2004-02-24 Pharmacia Corporation Preservative free ophthalmic oxazolidinone antibiotic drug delivery systems
WO2003033025A2 (en) * 2001-10-18 2003-04-24 Decode Genetics Ehf Cyclodextrin complexes
MXPA04008173A (es) * 2002-02-22 2004-11-26 Pharmacia Corp Formulaciones de farmaco antibiotico oftalmico que contienen un compuesto de ciclodextrina y cloruro de cetil piridinio.
US20050234018A1 (en) * 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye

Similar Documents

Publication Publication Date Title
JP2002523475A5 (ja)
JP2006526031A5 (ja)
CA2304669A1 (en) Acidic, thickened cleaning and disinfecting compositions
JP2007537301A5 (ja)
EP2153819A3 (en) Compositions containing therapeutically active components having enhanced solubility
JP2004508410A5 (ja)
JP2004536811A5 (ja)
CA2316539A1 (en) Sustained-release pharmaceutical composition
JP2005522421A5 (ja)
JPS54158409A (en) Liquid detergent composition
EP1053744A3 (en) Substituted phenols as fragrance, flavor and antimicrobial compounds
JP2005513006A5 (ja)
JP2007517945A5 (ja)
EP2157083A3 (en) Pharmaceutical compositions containing crystalline form (I) of lercanidipine hydrochloride
RU2006101675A (ru) Потребляемая пленка против зубного налета, освежающая дыхание
JPH0425319B2 (ja)
JP2009514786A5 (ja)
JP2006527285A5 (ja)
JP2005526149A5 (ja)
RU2001135821A (ru) Состав для полости рта, содержащий перлит
JP2003512511A5 (ja)
AU2003224059A1 (en) Hair care compositions containing phenolic styling agents
JP2007045864A5 (ja)
JP2000103709A5 (ja)
JP2005511529A5 (ja)